Chemical inhibitors of 1600015I10Rik can utilize various signaling pathways to achieve functional inhibition of the protein. Compounds such as Wortmannin and LY294002 are potent inhibitors of PI3K, which is crucial for AKT signaling. By blocking PI3K, these inhibitors prevent the phosphorylation and activation of AKT, a kinase that can directly or indirectly regulate the activity of 1600015I10Rik. The suppression of AKT activation by these inhibitors ensures that any downstream effects mediated by AKT, including the regulation of 1600015I10Rik, are also inhibited. Another inhibitor, Rapamycin, targets the mTOR pathway, which is involved in cell growth and proliferation. By inhibiting mTOR, Rapamycin can decrease the phosphorylation state of proteins that are regulated either directly or indirectly by mTOR, leading to a reduction in the functional activity of 1600015I10Rik.
The MEK inhibitors PD0325901 and U0126, by selectively blocking MEK, lead to a decreased activation of ERK, a kinase that can phosphorylate various substrates, including 1600015I10Rik. This inhibition can result in a lower level of phosphorylation and thus reduced activity of 1600015I10Rik. Similarly, Dasatinib acts by inhibiting tyrosine kinases, and if 1600015I10Rik is a substrate for these kinases, its phosphorylation and subsequent activity would be diminished. PP2, targeting Src family kinases, could also lead to decreased activation of 1600015I10Rik if it functions downstream of these kinases. Inhibitors that target stress-activated protein kinases, such as SP600125 for JNK and SB203580 for p38 MAPK, would disrupt the phosphorylation cascade that these kinases participate in, which could include the functional activation of 1600015I10Rik. Lastly, Gefitinib, Sorafenib, and Erlotinib, by inhibiting EGFR and RAF kinases respectively, can interrupt upstream signaling events that lead to the activation of ERK and PI3K pathways, culminating in the inhibition of 1600015I10Rik activity due to reduced phosphorylation and signaling throughput.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Inhibits PI3K which is downstream of AKT signaling, leading to the suppression of AKT activation. This reduction in AKT activity inhibits 1600015I10Rik. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
Blocks PI3K, decreasing AKT phosphorylation and activity, thereby inhibiting the activation of 1600015I10Rik which is downstream of the AKT pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Inhibits mTOR, which is part of the mTOR signaling pathway. Reduced mTOR activity leads to decreased phosphorylation and activation of 1600015I10Rik. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
Targets MEK, thereby inhibiting ERK activation. This blockade prevents the ERK-dependent phosphorylation and subsequent activation of 1600015I10Rik. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Tyrosine kinase inhibitor that prevents phosphorylation of substrates, including 1600015I10Rik if it is a tyrosine kinase or relies on tyrosine phosphorylation. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
Inhibits Src family kinases, potentially reducing the phosphorylation and activity of 1600015I10Rik if it operates downstream of these kinases. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
JNK inhibitor that would prevent JNK-mediated phosphorylation of 1600015I10Rik, assuming the protein's activity is regulated by JNK signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
p38 MAPK inhibitor, impeding p38-mediated signaling processes, which may include phosphorylation and activation of 1600015I10Rik. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
EGFR inhibitor which can reduce downstream signaling leading to the inhibition of 1600015I10Rik activation if it is part of the EGFR pathway. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
RAF inhibitor, which would inhibit the RAF/MEK/ERK pathway, potentially leading to reduced phosphorylation and activation of 1600015I10Rik. | ||||||